Viaskin Peanut for Peanut Allergy
(VITESSE Trial)
Trial Summary
What is the purpose of this trial?
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently on immunotherapy for any allergen or have used certain treatments like monoclonal antibodies within 6 months before the trial.
What data supports the effectiveness of the treatment Viaskin Peanut for peanut allergy?
Is Viaskin Peanut safe for people with peanut allergies?
How is the Viaskin Peanut treatment different from other peanut allergy treatments?
Viaskin Peanut is unique because it uses a patch to deliver small amounts of peanut protein through the skin, which helps desensitize the immune system to peanuts. This method, known as epicutaneous immunotherapy, is different from other treatments that might involve oral ingestion or avoidance strategies.13478
Eligibility Criteria
This trial is for peanut-allergic children aged 4-7 who react to a very small amount of peanut protein and are on a strict peanut-free diet. They must have certain levels of peanut-specific antibodies and skin test reactions. Kids with uncontrolled asthma, past immunotherapy for peanuts, or recent biologic treatments can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily DBV712 250 mcg or placebo for 12 months to assess efficacy and safety in inducing desensitization to peanut
Open-label Extension
Participants apply DBV712 250 mcg daily for an additional 24 or 36 months, depending on initial randomization, to continue treatment and assess sustained unresponsiveness
Follow-up
Participants are monitored for sustained unresponsiveness through open food challenges at 2, 4, and 6 months off treatment
Treatment Details
Interventions
- DBV712
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
DBV Technologies
Lead Sponsor